HOME >> MEDICINE >> NEWS
Starting dose of Lexapro as effective as optimally dosed Zoloft in the treatment of depression

NEW YORK, December 10 Forest Laboratories, Inc. (NYSE: FRX) announced today the results of a clinical study, which showed that LexaproTM (escitalopram oxalate) is as effective and well tolerated as Zoloft (sertraline hydrochloride). The purpose of the study was to evaluate whether the starting dose of Lexapro, 10 mg per day, could provide comparable efficacy to the full dosing range of Zoloft, 50 200 mg per day. Study results showed that patients receiving a dose of 10 mg per day of Lexapro experienced similar efficacy compared to patients receiving a median dose of Zoloft of 150 mg per day. At week four, 46 percent of Zoloft-treated patients received 150 mg per day or higher, and at week eight, 65 percent received 150 mg per day or higher. To achieve a dose of 150 mg per day or higher, patients treated with Zoloft required at least two dose titrations. Both Lexapro and Zoloft belong to a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). The study was presented in Puerto Rico at an annual meeting of neuropsychopharmacologists.

"In this study, most patients experienced relief from depressive symptoms. Patients treated with Lexapro received 10 mg throughout the study period, while patients treated with Zoloft received dosages based on depressive symptoms and the development of side effects," said George Alexopoulos, M.D., Professor of Psychiatry at Weill Medical College of Cornell University. "Lexapro is an effective treatment for depression with simple dosing that may improve patient adherence."

Each year, nearly 19 million adult Americans suffer from mild, moderate, or severe depression. One in 4 women and 1 in 10 men can expect to be diagnosed with depression during their lifetime. Depression costs the United States an estimated $44 billion each year. The World Health Organization predicts depression will become the leading cause of disability by the year 2020.

Study Conclusions<
'"/>

Contact: Charles E. Triano
212-224-6714
Forest Laboratories
10-Dec-2003


Page: 1 2 3

Related medicine news :

1. Starting beta-blocker before discharge in patients hospitalized for heart failure increases usage
2. Lexapro receives FDA approval for the treatment of generalized anxiety disorder
3. Strategy effective against drug resistant tuberculosis
4. Study shows patch therapy may be as effective as oral medications
5. Chronic pain treatments more effective when taken together, new study shows
6. Geodon effective in psychiatric emergencies; Sharply reduces time in restraints
7. Costs of antidepressants could have funded effective alternatives
8. New ways to design safer & more effective topical (transdermal) drug delivery announced in the PNAS
9. Government wasting your taxpayer money on ineffective drug cure
10. Neurobehavioral function during coma, stroke rehabilitation effective for elderly
11. European folic acid policies are not effective enough

Post Your Comments:
(Date:7/31/2015)... ... ... ZH Healthcare announces a new cloud based service delivering Health IT as ... Service (HITaaS) is a Healthcare dedicated cloud based service that sits over infrastructure as ... all aspects of infrastructure, security, runtime, middleware, OS, virtualization, Servers, storage, contracts, and ...
(Date:7/31/2015)... ... ... therapy for knee osteoarthritis is an important part of knee pain treatment. ... doing what they want or need to do. The patient may have trouble getting in ... exercise regime may be limited by the pain in their knee. When a patient sees ...
(Date:7/31/2015)... ... , ... New Energy Works Timberframers invites the public to join their timber ... from 9am – 12pm. Timber frame raisings are special, celebrating both craft ... the culmination of months of effort, planning, fundraising, and dreaming takes shape. , ...
(Date:7/31/2015)... , ... July 31, 2015 , ... The Radiology ... Michael Burgess, MD, (R-Tex) presenting “What’s Next for Health Care: A View From Capitol ... and founder of the Congressional Health Caucus, Rep. Burgess has a special understanding of ...
(Date:7/31/2015)... ... ... “ Crack’em ” was featured on NewsWatch as part of its monthly ... Forstrom, a technology expert and special reporter for NewsWatch, conducted the review and shared ... can be a very messy experience, especially when cracking eggs. Cracking an egg is ...
Breaking Medicine News(10 mins):Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3Health News:Make Less Mess while Cooking with Crack’em 2
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
(Date:7/30/2015)... FRANCISCO , July 30, 2015 ... market is expected to reach USD 23.01 million ... View Research, Inc. Growing base of geriatric population, increasing ... infections, and rising level of awareness among target customer ... rendering drivers over the forecast period. According to estimates ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5
Cached News: